AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20603300 — intervention group
Group type: COMPARATOR
Intervention: Control/reading group
Number of subjects: 47
Study 20603300 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with increased depressive symptoms
Number of subjects: 47
Study 17576075 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic induction by audiotape
Number of subjects: 0
Study 17576075 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic induction live
Number of subjects: 0
Study 17576075 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest design
Number of subjects: 0
Study 17576075 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective experiences and expectancies
Number of subjects: 0
Study 15920041 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high-intensity exercise (IHE)
Number of subjects: 7
Study 15920041 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity exercise (MOD)
Number of subjects: 7
Study 12855079 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-delivered exercise program
Number of subjects: 0
Study 12855079 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise program
Number of subjects: 0
Study 12855079 — intervention group
Group type: EXPERIMENTAL
Intervention: VR exercise program
Number of subjects: 0
Study 11847803 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 104
Study 11847803 — intervention group
Group type: COMPARATOR
Intervention: No-exercise
Number of subjects: 104
Study 9346976 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP
Number of subjects: 1293
Study 9346976 — intervention group
Group type: COMPARATOR
Intervention: DTwP
Number of subjects: 1293
Study 8416406 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-strength acellular pertussis vaccine (40 micrograms of pertussis proteins)
Number of subjects: 118
Study 8416406 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-strength acellular pertussis vaccine
Number of subjects: 118
Study 8416406 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarter-strength acellular pertussis vaccine
Number of subjects: 118
Study 8416406 — intervention group
Group type: COMPARATOR
Intervention: Standard adult tetanus-diphtheria vaccine alone
Number of subjects: 118
Study 3816923 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg controlled release (CR) tablets of salbutamol b.d.
Number of subjects: 20
Study 3816923 — intervention group
Group type: COMPARATOR
Intervention: 4 mg conventional tablets of salbutamol a.i.d.
Number of subjects: 20
Study 31961494 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 0
Study 31961494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31975122 — intervention group
Group type: EXPERIMENTAL
Intervention: VEPTR surgery with administration of preoperative antibiotics more than 30 minutes before surgery (or >60 minutes for vancomycin)
Number of subjects: 22
Study 31975122 — intervention group
Group type: EXPERIMENTAL
Intervention: VEPTR surgery with intraoperative temperature less than 35.0°C
Number of subjects: 22
Study 31975122 — intervention group
Group type: EXPERIMENTAL
Intervention: VEPTR surgery with assisted feeding
Number of subjects: 22
Study 31975122 — intervention group
Group type: EXPERIMENTAL
Intervention: VEPTR surgery in male patients
Number of subjects: 22
Study 31975122 — intervention group
Group type: EXPERIMENTAL
Intervention: VEPTR implant surgeries
Number of subjects: 22
Study 29901949 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 52
Study 29901949 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 52
Study 25049137 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention followed by self-regulatory intervention
Number of subjects: 205
Study 25049137 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulatory intervention followed by motivational intervention
Number of subjects: 205
Study 23326138 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic TME (LTME)
Number of subjects: 138
Study 23326138 — intervention group
Group type: COMPARATOR
Intervention: Open TME (OTME)
Number of subjects: 138
Study 20005697 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (D) with prednisone
Number of subjects: 1006
Study 20005697 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (M) with prednisone
Number of subjects: 1006
Study 20005697 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk groups classification
Number of subjects: 1006
Study 18434214 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation protocol
Number of subjects: 62
Study 18434214 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation protocol
Number of subjects: 62
Study 16650578 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha2M Val1000Ile polymorphism
Number of subjects: 551
Study 16650578 — intervention group
Group type: COMPARATOR
Intervention: Control group (no polymorphism)
Number of subjects: 551
Study 16650578 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha2M, LRP, RAP polymorphisms
Number of subjects: 551
Study 16650578 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha2M Val1000Ile allele frequencies
Number of subjects: 551
Study 16650578 — intervention group
Group type: EXPERIMENTAL
Intervention: LRP and RAP polymorphisms
Number of subjects: 551
Study 14518525 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLD-fMRI
Number of subjects: 22
Study 14518525 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS
Number of subjects: 22
Study 10657270 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled carbon dioxide (CO2)
Number of subjects: 0
Study 10657270 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary hyperventilation
Number of subjects: 0
Study 10657270 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary oxygen (6 litres/min)
Number of subjects: 0
Study 8866596 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol dry powder, 50 microg b.i.d. via a Diskhaler (n=92)
Number of subjects: 189
Study 8866596 — intervention group
Group type: COMPARATOR
Intervention: Dose‐titrated slow‐release theophylline capsules ('Theo‐Dur') b.i.d. (n=97)
Number of subjects: 189
Study 29861050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT) with normal PTF‐V1
Number of subjects: 941
Study 29861050 — intervention group
Group type: COMPARATOR
Intervention: Cardiac Resynchronization Therapy (CRT) with abnormal PTF‐V1
Number of subjects: 941
Study 26562186 — intervention group
Group type: EXPERIMENTAL
Intervention: PGX softgel
Number of subjects: 14
Study 26562186 — intervention group
Group type: COMPARATOR
Intervention: Rice flour softgel (control)
Number of subjects: 14
Study 25184941 — intervention group
Group type: EXPERIMENTAL
Intervention: Swiss Diagnosis Related Groups (SwissDRG)
Number of subjects: 395
Study 25184941 — intervention group
Group type: COMPARATOR
Intervention: Before SwissDRG
Number of subjects: 395
Study 25184941 — intervention group
Group type: EXPERIMENTAL
Intervention: After SwissDRG
Number of subjects: 395
Study 22972753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 114
Study 22972753 — intervention group
Group type: COMPARATOR
Intervention: Fibromyalgia education (FE)
Number of subjects: 114
Study 21168637 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency direct portacaval shunt (EPCS)
Number of subjects: 211
Study 21168637 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy (EST)
Number of subjects: 211
Study 21168637 — intervention group
Group type: COMPARATOR
Intervention: Unrandomized portacaval shunt (PCS)
Number of subjects: 211
Study 17656473 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements with IDPN
Number of subjects: 186
Study 17656473 — intervention group
Group type: COMPARATOR
Intervention: Oral nutritional supplements without IDPN
Number of subjects: 186
Study 17656473 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without IDPN)
Number of subjects: 186
Study 17656473 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in prealbumin >30 mg/L within 3 months
Number of subjects: 186
Study 16273458 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor conduction study (ulnar, peroneal nerve)
Number of subjects: 19
Study 16273458 — intervention group
Group type: EXPERIMENTAL
Intervention: F wave examination
Number of subjects: 19
Study 16273458 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory conduction study (ulnar, sural nerve)
Number of subjects: 19
Study 16273458 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic skin response (SSR)
Number of subjects: 19
Study 16273458 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability test at rest
Number of subjects: 19
Study 11870174 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose adjuvant interferon alfa-2b (IFNα2b)
Number of subjects: 0
Study 10192568 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain removed on postoperative day 3
Number of subjects: 90
Study 10192568 — intervention group
Group type: COMPARATOR
Intervention: Drain kept until discharge had decreased to less than 35 ml/24 hours
Number of subjects: 90
Study 7491817 — intervention group
Group type: EXPERIMENTAL
Intervention: PFP vaccine
Number of subjects: 47
Study 7491817 — intervention group
Group type: COMPARATOR
Intervention: TIV vaccine (control)
Number of subjects: 47
Study 2176794 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine hydrochloride
Number of subjects: 24
Study 2176794 — intervention group
Group type: COMPARATOR
Intervention: pH-adjusted 1.73% lidocaine (1 ml of NaHCO3 44.6 meq/L added to 10 ml of 2% lidocaine hydrochloride)
Number of subjects: 24
Study 529340 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (800 or 1600 IU) for 9 weeks or more
Number of subjects: 0
Study 529340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31831203 — intervention group
Group type: EXPERIMENTAL
Intervention: add-on ramelteon
Number of subjects: 120
Study 31831203 — intervention group
Group type: COMPARATOR
Intervention: haloperidol/risperidone
Number of subjects: 120
Study 30696266 — intervention group
Group type: EXPERIMENTAL
Intervention: Lip repair at 6 months and palate repair at 4 years
Number of subjects: 64
Study 30696266 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal lip repair and palate repair at 9 months
Number of subjects: 64
Study 30696266 — intervention group
Group type: EXPERIMENTAL
Intervention: Lip repair at 3 months and palate repair at 9 months
Number of subjects: 64
Study 30696266 — intervention group
Group type: COMPARATOR
Intervention: Control group (13 plaster casts of 8-year-old boys without UCLP)
Number of subjects: 64
Study 27380034 — intervention group
Group type: EXPERIMENTAL
Intervention: Monobloc appliance
Number of subjects: 165
Study 27380034 — intervention group
Group type: EXPERIMENTAL
Intervention: Bibloc appliance
Number of subjects: 165
Study 27380034 — intervention group
Group type: COMPARATOR
Intervention: Cost of treatment
Number of subjects: 165
Study 25308625 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose
Number of subjects: 292
Study 25308625 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of urine glucose
Number of subjects: 292
Study 23672972 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicanalicular silicone intubation for 8 weeks
Number of subjects: 120
Study 23672972 — intervention group
Group type: COMPARATOR
Intervention: No silicone intubation
Number of subjects: 120
Study 23672972 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicanalicular silicone intubation
Number of subjects: 120
Study 21356042 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous closure of PFO using the Amplatzer PFO Occluder
Number of subjects: 414
Study 21356042 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (warfarin for 6 months followed by antiplatelet agents)
Number of subjects: 414
Study 19416245 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 73
Study 19416245 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 73
Study 16194588 — intervention group
Group type: EXPERIMENTAL
Intervention: Achilles tendon rupture patients (3 subjects)
Number of subjects: 11
Study 16194588 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (8 subjects)
Number of subjects: 11
Study 15672950 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhouse made (IHM) embryo culture medium
Number of subjects: 100
Study 15672950 — intervention group
Group type: COMPARATOR
Intervention: Commercial Cook Sydney IVF Cleavage medium (SIC)
Number of subjects: 100
Study 15672950 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pregnancy rate per transfer
Number of subjects: 100
Study 15672950 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation rate
Number of subjects: 100
Study 11419834 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha-2A (subcutaneous injections)
Number of subjects: 32
Study 11419834 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone enemas
Number of subjects: 32
Study 9251875 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan
Number of subjects: 124
Study 9251875 — intervention group
Group type: COMPARATOR
Intervention: Oral sumatriptan
Number of subjects: 124
Study 8334908 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium hyaluronate (Healon) - 14 patients
Number of subjects: 34
Study 8334908 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% hydroxypropylmethylcellulose (HPMC) - 10 patients
Number of subjects: 34
Study 8334908 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscose - 10 patients
Number of subjects: 34
Study 3816835 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (loading dose followed by slow intravenous infusion over six hours, then oral therapy for five days, adjusted to maintain systolic pressure 100-120 mmHg)
Number of subjects: 166
Study 3816835 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 166
Study 29336835 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (77 Gy in 35 fractions)
Number of subjects: 571
Study 29336835 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated treatment (77 Gy in 35 fractions + integrated boost up to 95 Gy)
Number of subjects: 571
Study 29336835 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 571
Study 28237539 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus panitumumab (n = 400)
Number of subjects: 800
Study 28237539 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 plus bevacizumab (n = 400)
Number of subjects: 800
Study 26374482 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle-based intervention for 24 months
Number of subjects: 202
Study 26374482 — intervention group
Group type: COMPARATOR
Intervention: Standard stroke care (control)
Number of subjects: 202
Study 26374482 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle-based intervention
Number of subjects: 202
Study 24278929 — intervention group
Group type: EXPERIMENTAL
Intervention: Osstem TSIII HA implants (4.5 or 5.0 mm diameter, 10 mm long)
Number of subjects: 50
Study 24278929 — intervention group
Group type: COMPARATOR
Intervention: Zimmer TSV implants (4.7 mm diameter, 10 mm long)
Number of subjects: 50
Study 24278929 — intervention group
Group type: EXPERIMENTAL
Intervention: Both implant systems
Number of subjects: 50
Study 20299784 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast cereals and bread types
Number of subjects: 27
Study 18219661 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (treatment)
Number of subjects: 736
Study 18219661 — intervention group
Group type: COMPARATOR
Intervention: Zymed antibody (treatment)
Number of subjects: 736
Study 15965818 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovialitis score grading system
Number of subjects: 483
Study 15965818 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovialitis score of 4 points and more
Number of subjects: 483
Study 15965818 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of synovialitis score by gene expression data
Number of subjects: 483
Study 12186624 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide monotherapy
Number of subjects: 0
Study 12186624 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide (alone or as an adjuvant)
Number of subjects: 0
Study 12186624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen blockade with bicalutamide
Number of subjects: 0
Study 10351414 — intervention group
Group type: EXPERIMENTAL
Intervention: New medication for osteoarthritis
Number of subjects: 14
Study 10351414 — intervention group
Group type: COMPARATOR
Intervention: Managed care organizations (MCOs)
Number of subjects: 14
Study 7743286 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lignocaine ointment applied to the heel under an occlusive dressing for one hour before heel prick
Number of subjects: 30
Study 2382096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin treatment
Number of subjects: 0
Study 7138632 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium and magnesium aspartate (K + Mg Asp) - 7.2 g administered during a 24 h period prior to work
Number of subjects: 7
Study 7138632 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 7
Study 7138632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7138632 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium and magnesium aspartate (K + Mg Asp)
Number of subjects: 7
Study 30690128 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation (no treatment)
Number of subjects: 183
Study 30633959 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) 50 ppm for 24 hours
Number of subjects: 76
Study 30633959 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oxygen plus 50 ppm nitrogen) for 24 hours
Number of subjects: 76
Study 28628363 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventionist-guided weight loss program
Number of subjects: 246
Study 28628363 — intervention group
Group type: COMPARATOR
Intervention: Self-guided weight loss program
Number of subjects: 246
Study 26591552 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone as part of combination therapy for 3 months
Number of subjects: 50
Study 26591552 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 50
Study 23900134 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 0
Study 23900134 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 0
Study 23900134 — intervention group
Group type: COMPARATOR
Intervention: No TENS
Number of subjects: 0
Study 23900134 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional tasks
Number of subjects: 0
Study 21528639 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg (test formulation)
Number of subjects: 0
Study 21528639 — intervention group
Group type: COMPARATOR
Intervention: Reference product (control)
Number of subjects: 0
Study 19358416 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with a cytotoxic platinum agent
Number of subjects: 0
Study 19358416 — intervention group
Group type: COMPARATOR
Intervention: Cytotoxic agents alone
Number of subjects: 0
Study 16534013 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment
Number of subjects: 1061
Study 16534013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061
Study 12507703 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL 10‐0101 (peripherally selective KOR agonist)
Number of subjects: 6
Study 12507703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 11198708 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice and motivational enhancement in primary care
Number of subjects: 0
Study 11198708 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary health evaluation in a detoxification unit
Number of subjects: 0
Study 11198708 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital treatment
Number of subjects: 0
Study 11198708 — intervention group
Group type: EXPERIMENTAL
Intervention: Case monitoring for alcoholics
Number of subjects: 0
Study 9011784 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-allergen immunotherapy (subcutaneous injections of a mixture of up to seven aeroallergen extracts)
Number of subjects: 121
Study 9011784 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous injections of placebo)
Number of subjects: 121
Study 9011784 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-allergen immunotherapy
Number of subjects: 121
Study 9011784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 8493012 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity testing
Number of subjects: 448
Study 8493012 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast sensitivity testing
Number of subjects: 448
Study 8493012 — intervention group
Group type: EXPERIMENTAL
Intervention: Color vision testing
Number of subjects: 448
Study 8493012 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual field testing
Number of subjects: 448
Study 8493012 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI changes
Number of subjects: 448
Study 8493012 — intervention group
Group type: COMPARATOR
Intervention: Clinical and MRI evidence of multiple sclerosis
Number of subjects: 448
Study 3124427 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (400 mg in a single dose)
Number of subjects: 199
Study 3124427 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime (1.5 g given twice with an 8-hour interval)
Number of subjects: 199
Study 3124427 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Doxycycline and Cefuroxime)
Number of subjects: 199
Study 30541221 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg) 20 min before anesthesia induction, followed by 0.2 μg·kg(‐1)·h(‐1) intraoperatively.
Number of subjects: 100
Study 30541221 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (0.1 μg·kg(‐1)·h(‐1)) plus sufentanil (0.025 μg·kg(‐1)·h(‐1)) for PCA in group D.
Number of subjects: 100
Study 30541221 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group (D).
Number of subjects: 100